What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor?
An intraclass switch following IL-17A inhibitors failure yielded better treatment outcomes than a switch to guselkumab.
Authors
- Yizhang Liu (ORCID: https://orcid.org/0009-0001-0465-2829)
- Yehong Kuang (ORCID: https://orcid.org/0000-0002-1133-1791)
- Kun Hu (ORCID: https://orcid.org/0000-0001-9717-4012)
- Junchen Chen (ORCID: https://orcid.org/0000-0001-7553-0880)
- Shuangyuan Zhou
- Panpan Liu (ORCID: https://orcid.org/0000-0002-0828-5931)
- Mi Zhang (ORCID: https://orcid.org/0000-0001-6795-0076)
- Yongfang Duan
Institutions
- Central South University (CN)
- SKiN Health (CA)
- Parker Institute for Cancer Immunotherapy (US)
- Hunan Cancer Hospital (CN)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1080/09546634.2025.2588072
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00